Introduction
Heart failure (HF) is a significant health problem 1, 2 that is associated with high rates of morbidity and mortality, especially in African Americans (AAs) and Hispanics. 1, 3, 4 The higher mortality in these groups has been attributed to differences in the severity and causes of HF, the prevalence of coexisting conditions and risk factors, 2 socioeconomic and cultural factors, and access to high-quality medical care. 5 β-blockers (BBs) are beneficial in patients with symptomatic HF or left ventricular (LV) systolic dysfunction. 6 -8 Funding for this project was provided by the Congestive Heart Failure Division Fund, Montefiore Medical Center. These data were presented in part at the 13th Annual Scientific Meeting of the Heart Failure Society of America, September 2009, Boston, Massachusetts. Dr. Kelesidis contributed to collecting the data, quantitation of echocardiograms, data analysis, and writing and editing the manuscript. Dr. Varughese contributed to collecting the data, data analysis, and writing and editing the manuscript. Dr. Hourani contributed to collecting the data, and writing and editing the manuscript. Dr. Zolty contributed to conceiving the study, quantitation of echocardiograms, data analysis, and writing and editing the manuscript. The authors have no other funding, financial relationships, or conflicts of interest to disclose.
However, response to β-blockers may vary among different ethnic groups. 9 -11 Overall, BBs have been shown to have similar benefits in both AAs and Caucasians. 12, 13 Previous HF studies have generally been limited to comparisons between AAs and Caucasian populations, 2 but there are few comparative statistics concerning HF in Hispanics, 1 the fastest-growing segments of the US population. 14 Although substantial information is available on racial differences in mortality and risk factors, much less is known about racial differences in noninvasive measures of HF, such as parameters of LV remodeling. LV remodeling parameters such as left ventricular ejection fracture (LVEF), left ventricular end-diastolic diameter (LVEDD), and degree of mitral regurgitation (MR) have prognostic significance in patients with HF. 15 Data accounting for the influence of BB treatment on parameters of LV remodeling in Hispanic population are scarce.
In this project, we aimed to assess the magnitude of improvement of LV function and other parameters of remodeling after use of BBs, analyze the predictors responsible for the individual variation, and evaluate the different effect of BB therapy on LVEF and other parameters of remodeling in Hispanic patients with HF compared with other ethnic groups. 
Study Design
The clinical design was a retrospective study aimed at analyzing the effects of BBs on cardiac reverse remodeling among a multiethnic population. Approval was granted from the AECOM institutional review board. BBs were titrated up to the maximum tolerable dose without a predefined time schedule. The maximum tolerable dose was the daily dose over which there was either (1) aggravation of dyspnea or edema, (2) systolic BP <90 mm Hg or HR <60 beats per minute at rest, or (3) a need to increase the concomitant medication for HF. The assignment of race was done by physicians and nurse coordinators. The charts of patients who had LVEF, LVEDD, and degree of MR measured using 2-dimensional echocardiography and the modified Simpson's rule at baseline (time point of available data when patient was not receiving BBs), and 12 months after a stable dose of BBs were reviewed. LV dysfunction was defined as an LVEF ≤0.40. LVEF was our primary measure of systolic function. Degree of MR was utilized for valvular function, whereas measures of diastolic function were analyzed using the LVEDD, which has been shown in previous studies to be a strong factor in predicting occurrence of reverse remodeling. 2 Severity of MR was originally classified as none, mild, moderate, moderate-severe, or severe as per interpreting echocardiographer.
As in previous studies, 7, 16 LVEF responders to β-blockade were defined as patients with an absolute increase in LVEF ≥5% after a maximal doses of BBs. Similar to other studies, 17, 18 LVEDD responders to BBs were defined as patients with an absolute improvement in LVEDD ≥10% from baseline after maximal doses of BBs. LVEF decline was defined as patients with a decline in LVEF ≥5%, and LVEDD decline was defined as worsening of LVEDD ≥10% from baseline. MR response was defined as ≥1 degree improvement after maximal doses of BBs. MR decline was defined as ≥1 degree of MR deterioration after maximal doses of BBs. A high dose of BBs was defined similarly to prior studies. 6, 7, 19 For example, a high dose of metoprolol was defined as ≥150 mg orally daily, whereas a high dose of carvedilol was defined as ≥50 mg orally daily. A simple and multivariable linear regression analysis was performed between the changes of LVEF ( LVEF) and LVEDD ( LVEDD) from baseline to stable dose and the available covariates including patient characteristics, and concomitant medication to identify predictors of improvement after BBs and how these predictors differ among ethnic groups. To determine important predictors of reverse remodeling, we also performed multivariable logistic regression using LVEF response, LVEDD response, and MR response as binary outcomes separately. (49.06%), fewer patients with New York Heart Association (NYHA) class I (6.29%) and more patients with higher than class III NYHA (25.78%) (P < 0.01) compared to other races. Regarding medication use (Table 2) , 220 patients (52.63%) received carvedilol, whereas 198 patients (47.37%) received metoprolol. Table 3 shows baseline parameters of LV remodeling (LVEF, LVEDD, degree of MR) and their respective values after 1 year of β-blockade. Compared to other races (P < 0.01), Hispanics had worse LVEF (34%), had the least improvement in LVEF (2%), had fewer patients with LVEF response (42.77%) and more patients with LVEF decline (24.53%), had no improvement in LVEDD, had fewer patients with LVEDD response (5.03%) and more patients with LVEDD decline (10.69%), had no improvement in degree of MR and fewer patients with degree of MR response (16.35%).
Statistical Analyses

LV Remodeling Improvement After β-Blockade
When we stratified our analysis by categories of response (remodeling responders vs nonremodeling responders), we found similar results (Table 3) .
Clinical Predictors of Reverse Remodeling
In bivariate analysis, there was a significant correlation of median change of LVEF (δLVEF) with Hispanic race (r = −0.270, P < 0.001), Caucasians (r = 0.456, P < 0.001), ischemic cardiomyopathy (r = −0.141, P < 0.001), NYHA (r = <0.73, P < 0.001), alcohol use (r = 0.127, P < 0.05), BB dose (r = 0.136, P < 0.001). Similar results were noted for LVEF response and LVEF decline. Moreover, there was a significant correlation of median change of LVEDD (δLVEDD) with Hispanic race (r = −0.304, P < 0.001), Caucasians (r = 0.270, P < 0.001), ischemic cardiomyopathy (r = −0.175, P < 0.001), and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) (r = −0.197, P < 0.001). Similar results were noted for LVEDD response and LVEDD decline. Finally, MR response had a significant association with Hispanic race (r = −0.194, P < 0.001) and Caucasians (r = 0.366, P < 0.001) but not with BB dose or ACEI/ARB. Multivariable linear regression (Table 4) revealed that Hispanic and AA race were negative predictors of change in LVEF in contrast to Caucasians. In the adjusted analysis, significant predictors of LVEF change were NYHA class (P < 0.01), medium dose of BB (P < 0.01), high dose of BB (P < 0.05) but not ACEI/ARB, gende and age. Similarly to LVEF change, different races (P < 0.001) and a high dose of BBs (P = 0.05) were important predictors of LVEDD change (δLVEDD). Differences of individual predictors of remodeling stratified by racial groups are also shown.
Similar results were noted in multivariable logistic analysis (Table 5) . Hispanic race was a significant predictor of LVEF response (odds ratio [OR]: = 0.858, P < 0.001), LVEDD response (OR: 0.916, P < 0.01) but not MR response (OR: 0.988, P = 0.07). Finally, when LVEF or LVEDD decline were used as outcomes, we found similar results. Hispanic race was an important predictor of LVEF decline (OR: 2.577, P < 0.001) and LVEDD decline (OR: 2.699, P < 0.05) but not of MR decline (OR: 1.641, P = 0.547).
Discussion
The major finding of this study was that improvement in parameters of cardiac remodeling, such as LVEF, LVEDD, and degree of MR, were not evident after 1 year of BB therapy among Hispanics with chronic HF compared with other races. Abbreviations: AA, African American; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, β-blocker; CI, confidence interval; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; MR, mitral regurgitation; OR, odds ratio. OR for Hispanic and AA is shown using Caucasian as the reference category, and medium-and high-dose ORs are shown using low-dose BB as the reference category.
fewer patients with LVEF, LVEDD, and MR response. In multivariable adjusted analysis, Hispanic and AA race were important predictors of LVEF and LVEDD (P < 0.01) but not MR response. Therefore, there seems to be ethnic variability in the effects of BBs on cardiac remodeling. The different reverse remodeling to BBs among different ethnic groups can be explained by a few factors. 10, 11, 20 Due to the diversity of both the patients and drugs, it is difficult to provide a common interpretation in regard to the effects of these agents in AA and Caucasian patients; but in general, similar benefits have been described in both of these races. 13 Exception to this was the Beta-Blocker Evaluation of Survival Trial (BEST) trial, in which AA patients did much worse than Caucasians due to genetic differences. 21 Conflicting data regarding response to different BBs 22, 23 may not be a result of study design, but rather an inherent difference in response to therapies. This is supported by a genetic substudy of the BEST data, which evaluated the effects of BBs among differing B gene polymorphisms. Those with certain β-receptor genotypes were associated with the better clinical response to BBs compared to others. 24 -28 Moreover, a difference in reverse remodeling can be explained by differences among ethnicities in respect to ancestry/race, 29 socioeconomic factors, 5 and dietary and lifestyle risk factors for CVD. 30 However, our study was not designed to explain why LVEF and LVEDD response seems to differ in different ethnicities. In this regard, the interactions between race and access to high-quality HF care remain important areas for future investigation, and future research aimed at analyzing polymorphisms among Hispanics and AAs may yield interesting results.
Our study showed a beneficial role of BB in remodeling parameters in AAs and Caucasians. These findings are consistent with prior studies that showed that treatment with carvedilol had significantly favorable effects on LV enddiastolic volumes, LVEF, and degree of MR. 7, 31, 32 In our study, overall the reverse remodeling to BBs was similar in patients with ischemic and nonischemic cardiomyopathy as has been previously shown in other studies. 7, 32, 33 We also confirmed the finding that the effect of BBs on LV remodeling was similar irrespective of type of BB used (metoprolol or carvedilol). 34 -36 Interestingly, we found that improvement in parameters of cardiac remodeling, such as LVEF, LVEDD, and degree of MR, were not evident after 1 year of BB therapy among Hispanics with chronic HF compared with other races. To our knowledge, this is 1 of the first studies that examined differences in cardiac remodeling between AA and Hispanics. Although the Hispanic population has been shown to comprise a high-risk cardiovascular group, 37 -39 there are very limited data on Hispanic patients with chronic systolic HF. 3 AAs have been under-represented in major HF trials, whereas Hispanic patients have been nearly absent in most clinical trials, and thus there are very limited data regarding the effect of medications such as BBs in this ethnic group. Although LV remodeling patterns on Hispanic subgroups compared with nonHispanic whites have been examined in the Multi-Ethnic Study of Atherosclerosis (MESA) study, 38 ,39 these patterns have not been associated with the use of BBs. In accordance with these studies, we adjusted our models of remodeling for age, sex, diabetes, smoking, and use of antihypertensive medications, 38, 39 and we found similar magnitude difference of abnormal remodeling between Hispanics and Caucasians. Therefore, our data confirm prior findings that Hispanics have differences in ventricular remodeling compared with other races. 40 Finally, we extended this finding by showing that Hispanics have worse LV reverse remodeling compared to other races after 1 year of BBs.
Our study also showed that BB dose was also 1 of the strongest predictors of remodeling response compared with other predictors such as age, gender, ACEI, and type of cardiomyopathy. Regarding dosing of BBs, in the Multicenter Oral Carvedilol Heart Failure Assessment (MOCHA) trial, carvedilol (12.5-50 mg/day) generated dose-related LVEF improvement (5%-8%) in HF patients, of whom 77% were Caucasians. 6 The carvedilol dose in our patients was about the same dose as that used in the MOCHA trial, but the magnitude of the LVEF improvement for Caucasians in our study was higher. Although this finding is consistent with other studies, 34, 35 to the best of our knowledge there are no prior studies regarding BB dosing and LV reverse remodeling in Hispanics.
Finally, in our study we showed that BB use was a stronger predictor of remodeling response than the use of ACEIs. The majority of our patients had nonischemic cardiomyopathy (NICM). This finding is consistent with prior studies that have shown that BB therapy was more effective on LV remodeling in nonischemic than in ischemic cardiomyopathy. 41 However, the focus of our study was not to compare whether use of BBs is a stronger predictor of reverse remodeling compared with ACEI in different races.
Due its retrospective nature, our study had expected limitations. The number of patients enrolled in this study precluded restriction of analyses to only those with low ejection fraction or only those with symptoms of HF. Those variables that were determined by self-report or review of the medical record are beyond the control of the investigators and thus subject to error. There was also lack of availability of data on clinical outcomes, medical therapy, and lack of information regarding socioeconomic status, including education and income, that may have had an effect on HF outcomes. In addition, this is a single-center study, and the findings may not confer external validity. In our Hispanic population, we did not identify special subgroups such as Mexican-origin Hispanic vs Caribbean-origin Hispanic, which have been shown to have differences in LV remodeling parameters. 38, 39 Finally, the methods used in this study serve only to describe statistical associations between variables, which are not necessarily proof of causation.
Conclusion
Our results indicate that among Hispanics, the effects of β-adrenergic blockade and its expected improvement in LV function, LVEDD, and MR, as measures of cardiac remodeling, were not apparent after 1 year of therapy. Furthermore, among HF patients who took BBs for 1 year, there is a high proportion of nonresponders who actually decreased their LVEF significantly, mostly in
